SITC 2026 has ended. This guide stays up as the record of who was there. Next: SITC 2027, Nov 3–7, 2027 in National Harbor

Who’s Going to SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

661 organizations at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, a ~6,000-person, evenly mixed academic & biopharma meeting of cancer immunotherapy researchers, oncologists and drug developers. As of Nov 2, 2026.

Format
Research topic
Top represented
Showing 1–1 of 661 organizations
OrganizationSITC 2026 Attendance
Cancer centres & hospitals
University of Texas comprehensive cancer center in Houston focused on cancer patient care, research and education.
Session
Thu Nov 5
12:00pm–1:30pm
Workshop
Thu Nov 5
7:00pm–8:00pm
Early Career Scientist Speed Mentoring
  1. 7:00pm–8:00pmSpeed Mentoring - Group Mentoring
  2. 7:00pm–7:30pmSpeed Mentoring - One-on-One
  3. 7:30pm–8:00pmSpeed Mentoring - One-on-One 2
Poster
Fri Nov 6
12:15–1:45pm
5:30–7pm
Poster
Sat Nov 7
12–1:30pm
6:40–8:10pm
Poster
Sat Nov 7
12–1:30pm
6:40–8:10pm
Session
Sat Nov 7
3:30pm–4:50pm
Oral Abstract Session 3
  1. 3:33pm–3:48pmClinical and translational evaluation of lifileucel in patients with metastatic undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.Memorial Sloan Kettering Cancer Center
  2. 3:48pm–4:03pm3-Year landmark overall survival and quality-adjusted overall survival with RP1 combined with nivolumab in anti–PD-1–failed melanoma: Results from the IGNYTE trialUSC Norris Comprehensive Cancer Center
  3. 4:03pm–4:18pmThe SPEARHEAD-1 Trial of Afamitresgene autoleucel (Afami-cel) in Advanced Synovial Sarcoma: Factors Associated with Clinical OutcomesMemorial Sloan Kettering Cancer Center
  4. 4:18pm–4:33pmInitial clinical results from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBCMass General Brigham Cancer Institute
  5. 4:33pm–4:48pmMDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory DiseaseNational Cancer Institute Pascale

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from companies at SITC 2026

Tell us what you sell and we’ll find the people at these companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

When and where was SITC 2026?

SITC 2026 Annual Meeting ran November 4–8, 2026, at the Phoenix Convention Center in Phoenix, AZ.

What conference is this?

The SITC Annual Meeting is the yearly meeting of the Society for Immunotherapy of Cancer, the professional society for cancer immunotherapy. SITC 2026 — its 41st meeting and pre-conference programs — runs November 4–8, 2026 at the Phoenix Convention Center, bringing together academic and clinical immunotherapy researchers, oncologists, drug developers and the companies that supply them.

What is in this guide?

Every organization we can place at SITC 2026: 1,200 people on the public program — invited speakers, session chairs, moderators, panelists, lunch-table experts and pre-conference program organizers (205 talks, 91 of them oral abstracts, across 94 sessions and programs), and the presenting authors of 1,009 posters — rolled up to their cancer centres, universities and companies, plus the 138 exhibitors on the floor plan with their booth numbers and the companies hosting sponsored symposia and tech talks: 661 organizations in one list. People appear as credentials or roles, never by name. An abstract counts only its presenting author’s institution, never its co-authors’.

Where do the named attendees come from?

From their own public posts. 5 people said on LinkedIn or Bluesky that they will be at SITC 2026, or were named in their organization’s post about it, across 4 posts. Each shows as a short quote from the post, with every person’s name removed, linked to the post itself. Posts that only promote a company, or that never say who will attend, are left out, and so is anyone already on the program.

How are organizations typed?

By the role an organization plays in cancer immunotherapy: universities and research institutes, cancer centres and hospitals, and government and non-profit bodies; pharma and biotech drug developers; then the suppliers — research tools and software, diagnostics, and CROs, other services and investors. Research topics come from each talk’s, poster’s and session’s own title, or from an exhibitor’s own profile.

How current is it?

Pulled from the public schedule, SITC’s list of accepted abstracts and the exhibitor floor plan on November 2, 2026 — the late-breaking abstract titles SITC released on October 28 included — and from people’s own LinkedIn and Bluesky posts on September 29. Exhibit-hall hours are the poster hall’s published hours.

Browse SITC 2026 by

Exhibit hall

Organizations with their own page

493 organizations — every exhibitor, every company with talks or known attendees, and every organization with 2 or more presentations.

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction